Table 3 Bivariate analysis of the relationship of nutritional status on follow-up of patients with different studied variables

Sex

0.854^*

Male

6 (13.0)

25 (54.3)

15 (32.6)

Female

9 (10.7)

44 (52.4)

31 (36.9)

Nationality

0.018^*

Bahraini

15 (13.4)

54 (48.2)

43 (38.4)

Non-Bahraini

0 (0.0)

15 (83.3)

3 (16.7)

Type of delivery, (n = 54)

0.030^*

Vaginal

8 (17.0)

28 (59.6)

11 (23.4)

Caesarean

0.0 (0.0)

2.0 (28.6)

5.0 (71.4)

Birth weight (kg), (n = 57)

3.0 (2.8–3.3)

3.1 (3.0-3.4)

3.0 (2.7–3.7)

0.645^†

Age at presentation (yr)

9.3 (4.9–12.3)

11.2 (9.1–12.7)

11.0 (9.6–13.6)

0.184^†

Age group at presentation (yr)

0.020^*

Very early onset (< 6 year)

5 (31.3)

5 (31.5)

6 (37.5)

Non-very early onset (6–18 year)

10 (8.8)

64 (56.1)

40 (35.1)

Type of IBD

0.093^*

Crohn’s disease

10 (13.7)

43 (58.9)

20 (27.4)

Ulcerative colitis

5 (8.8)

26 (45.6)

26 (45.6)

Prediagnosis disease duration (mo), (n = 65)

1.0 (1.0–4.0)

1.3 (0.3-4.0)

3.0 (0.4-5.0)

0.784^†

Postdiagnosis disease duration (yr)

5.3 (0.9–8.6)

3.4 (1.1–8.6)

9.2 (2.5–17)

0.005^†

Extraintestinal manifestation, (n = 120)

0.229^*

Yes

3 (6.4)

29 (61.7)

15 (31.9)

No

12 (16.4)

37 (50.7)

24 (32.9)

Growth parameters at presentation

Weight (kg), (n = 95)

19.2 (15.8–27.8)

29.6 (23.0-34.7)

43.6 (27.8–52.0)

< 0.001^†

Height (cm), (n = 79)

128.1 ± 22.5

135.4 ± 17.0

142.2 ± 16.0

0.103^‡

BMI (kg/m²), (n = 79)

13.2 (12.1–14.3)

15.4 (14.2–17.3)

21.7 (17.9–23.4)

< 0.001^†

Age at last growth parameters (yr)

13.3 (12.1–18.5)

13.8 (12.4–20.3)

16.9 (14.0-29.2)

0.002^†

Age at last growth parameters (yr)

0.023^*

≤18

13 (15.1)

49 (57.0)

24 (27.9)

>18

2 (4.5)

20 (45.5)

22 (50.0)

Laboratory markers

Hematocrit (%), (n = 127)

25.8 (22.5–29.4)

31.5 (27–36)

31.7 (27.9–37.5)

0.017^†

ESR (mm/h), (n = 120)

30 (22–40)

26 (15–45)

20 (11–46)

0.274^†

CRP (mg/dL), (n = 118)

43.6 (25.6–73.4)

14.6 (1.7–48.2)

4.7 (1.1–27.8)

0.007^†

IBD disease activity, (n = 121)

0.831^*

Mild

3 (10)

19 (63.3)

8 (26.7)

Moderate

5 (11.1)

25 (55.6)

15 (33.3)

Severe

7 (15.2)

23 (50.0)

16 (34.8)

Medication used, (n = 119)

15 (12.6)

63 (52.9)

41 (34.5)

Prednisolone

0.158^*

Yes

14 (14.9)

51 (54.3)

29 (30.9)

No

1 (4.0)

12 (48.0)

12 (48.0)

Azathioprine

0.026^*

Yes

12 (14.1)

38 (44.7)

35 (41.2)

No

1 (2.9)

24 (70.6)

9 (26.5)

Mesalazine

0.166^*

Yes

11 (15.1)

35 (47.9)

27 (37.0)

No

2 (4.3)

27 (58.7)

17 (37.0)

Biological therapy

0.208^*

Yes

10 (18.2)

26 (47.3)

19 (34.5)

No

5 (7.8)

37 (57.8)

22 (34.4)

Exclusive enteral nutrition

0.566^*

Yes

0 (0.0)

5 (62.5)

3 (37.5)

No

15 (12.3)

64 (52.5)

43 (35.2)